These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18769218)

  • 1. Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy.
    Gianoukakis AG; Smith TJ
    Curr Opin Endocrinol Diabetes Obes; 2008 Oct; 15(5):446-52. PubMed ID: 18769218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
    Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
    Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Graves' ophthalmopathy.
    Salvi M
    Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):409-14. PubMed ID: 25105999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interactions of fibroblasts, adipocytes and immunocompeent cells in the pathogenesis of endocrine ophthalmopathy].
    Heufelder AE
    Acta Med Austriaca; 2001; 28(4):89-92. PubMed ID: 11593897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
    Wall JR; Lahooti H
    Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.
    Dik WA; Virakul S; van Steensel L
    Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
    Janssen JAMJL; Smith TJ
    Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of ophthalmopathy in autoimmune thyroid disease.
    Heufelder AE
    Rev Endocr Metab Disord; 2000 Jan; 1(1-2):87-95. PubMed ID: 11704996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
    Wall JR; Lahooti H
    Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
    Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy: correlation with clinical features.
    Gopinath B; Musselman R; Adams CL; Tani J; Beard N; Wall JR
    Thyroid; 2006 Oct; 16(10):967-74. PubMed ID: 17042681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TSHR as a therapeutic target in Graves' disease.
    Smith TJ
    Expert Opin Ther Targets; 2017 Apr; 21(4):427-432. PubMed ID: 28127991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies.
    Khoo TK; Bahn RS
    Thyroid; 2007 Oct; 17(10):1013-8. PubMed ID: 17935483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.
    Wang Y; Smith TJ
    Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1735-48. PubMed ID: 24651704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
    van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
    Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of Graves' orbitopathy: a 2010 update.
    Smith TJ
    J Endocrinol Invest; 2010 Jun; 33(6):414-21. PubMed ID: 20631493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current understanding of pathogenesis of Graves ophthalmopathy].
    Ando T; Eguchi K
    Nihon Rinsho; 2006 Dec; 64(12):2275-8. PubMed ID: 17154091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.
    Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP
    Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunopathogenesis of thyroid eye disease: emerging paradigms.
    Naik VM; Naik MN; Goldberg RA; Smith TJ; Douglas RS
    Surv Ophthalmol; 2010; 55(3):215-26. PubMed ID: 20385333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.